Isomorphic Labs reportedly seeks funding at a valuation of at least $40 billion

Company Background

Isomorphic Labs was founded in 2021 as a spin-off of Google DeepMind and is led by CEO Demis Hassabis. Its core product is IsoDDE, a drug discovery platform that builds on AlphaFold, DeepMind's technology for predicting protein structures.

Funding History

The company has received significant funding from investors such as Thrive Capital and Alphabet, with a total of approximately $2.7 billion in disclosed external funding since its founding. In May 2026, Isomorphic closed a $2.1 billion Series B round, which was led by Thrive Capital and included investments from Alphabet and the UK Sovereign AI Fund.

Partnerships and Milestones

Isomorphic has partnerships with major pharmaceutical companies like Eli Lilly and Novartis, and has announced deals with these companies that carry potential milestone payments of more than $3 billion combined. The company plans to start first-in-human trials by the end of 2026, which will determine whether it shifts from a promising software company to an actual drug developer.

Clinical Gap

Isomorphic has not released any clinical data and has not dosed any patients. Despite this, the company is in talks to raise money at a valuation of at least $40 billion, with potential for a higher valuation of $50 billion.